Payment overview · 2025
General Payments
$1,488.77
84 reported records · 22 companies
Healthcare provider profile · identity verified
Nabil Keith, MD
Allopathic & Osteopathic Physicians|Family Medicine · DAWSONVILLE, GA · NPI 1306032198
Verified facts
What the public records show
CMS Open Payments records show Nabil Keith, MD received $1,488.77 in general payments during 2025 across 84 reported records.
ABBVIE INC. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti, Rybelsus, Synthroid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 397 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.91 | 12.8% | 21 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $170.89 | 11.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $169.38 | 11.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.35 | 10.0% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $123.62 | 8.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.44 | 6.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.73 | 5.4% | 3 | 2025 |
| KVK-Tech, Inc. | Unresolved — no canonical attribution shown | $73.23 | 4.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.85 | 4.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.70 | 3.7% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.32 | 3.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.44 | 3.5% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $34.74 | 2.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.60 | 2.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.37 | 1.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.54 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.47 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.39 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.24 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.80 | 1.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.94 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,488.77 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $294.51 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $137.26 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.37 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.36 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.36 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.86 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.73 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.25 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $55.70 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $53.32 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.27 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.27 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $31.00 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.48 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $12.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 98 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
98 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
98 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
397 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1248 | 104 |
| Sertraline Hcl | Sertraline Hcl | 836 | 52 |
| Omeprazole | Omeprazole | 794 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 789 | 79 |
| Gabapentin | Gabapentin | 761 | 75 |
| Trazodone Hcl | Trazodone Hcl | 743 | 60 |
| Donepezil Hcl | Donepezil Hcl | 699 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 662 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 90 |
| Lisinopril | Lisinopril | 573 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 557 | 68 |
| Mirtazapine | Mirtazapine | 540 | 28 |
| Buspirone Hcl | Buspirone Hcl | 539 | 28 |
| Furosemide | Furosemide | 507 | 59 |
| Memantine Hcl | Memantine Hcl | 492 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 461 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 452 | 46 |
| Potassium Chloride | Potassium Chloride | 428 | 44 |
| Eliquis | Apixaban | 397 | 32 |
| Famotidine | Famotidine | 397 | 26 |
| Olanzapine | Olanzapine | 379 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 365 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 347 | 29 |
| Metformin Hcl | Metformin Hcl | 342 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 31 |
| Carvedilol | Carvedilol | 325 | 34 |
| Risperidone | Risperidone | 291 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 289 | 31 |
| Montelukast Sodium | Montelukast Sodium | 278 | 19 |
| Losartan Potassium | Losartan Potassium | 248 | 43 |
| Divalproex Sodium | Divalproex Sodium | 237 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 210 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 22 |
| Levetiracetam | Levetiracetam | 187 | 13 |
| Topiramate | Topiramate | 162 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 148 | 19 |
| Allopurinol | Allopurinol | 144 | 16 |
| Meloxicam | Meloxicam | 141 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 14 |
| Lamotrigine | Lamotrigine | 131 | suppressed |
| Bupropion Xl | Bupropion Hcl | 128 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 128 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 127 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 127 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 26 |
| Aripiprazole | Aripiprazole | 121 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 33 |
| Prednisone | Prednisone | 117 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 111 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 11 |
| Baclofen | Baclofen | 104 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 102 | suppressed |
| Xarelto | Rivaroxaban | 102 | suppressed |
| Atenolol | Atenolol | 101 | 15 |
| Ezetimibe | Ezetimibe | 101 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 99 | suppressed |
| Rexulti | Brexpiprazole | 98 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 96 | suppressed |
| Alprazolam | Alprazolam | 96 | 30 |
| Oxcarbazepine | Oxcarbazepine | 91 | suppressed |
| Torsemide | Torsemide | 91 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 90 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | suppressed |
| Azithromycin | Azithromycin | 89 | 73 |
| Myrbetriq | Mirabegron | 86 | suppressed |
| Sucralfate | Sucralfate | 86 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | suppressed |
| Lorazepam | Lorazepam | 84 | 19 |
| Clonazepam | Clonazepam | 83 | 21 |
| Simvastatin | Simvastatin | 81 | 22 |
| Celecoxib | Celecoxib | 78 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 76 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 75 | suppressed |
| Carbamazepine | Carbamazepine | 73 | suppressed |
| Ondansetron Odt | Ondansetron | 70 | 31 |
| Farxiga | Dapagliflozin Propanediol | 67 | 11 |
| Pregabalin | Pregabalin | 67 | 11 |
| Propranolol Hcl | Propranolol Hcl | 66 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 63 | suppressed |
| Sotalol | Sotalol Hcl | 62 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 48 |
| Bupropion Hcl | Bupropion Hcl | 58 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 58 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 58 | 58 |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Vascepa | Icosapent Ethyl | 57 | suppressed |
| Amantadine | Amantadine Hcl | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 53 |
| Divalproex Sodium Er | Divalproex Sodium | 56 | suppressed |
| Lacosamide | Lacosamide | 55 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 55 | suppressed |
| Spironolactone | Spironolactone | 55 | 11 |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | suppressed |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Ranolazine Er | Ranolazine | 52 | suppressed |
| Valproic Acid | Valproic Acid | 52 | suppressed |
| Calcium Acetate | Calcium Acetate | 51 | suppressed |
| Glimepiride | Glimepiride | 51 | suppressed |
| Cephalexin | Cephalexin | 49 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 49 | suppressed |
| Jardiance | Empagliflozin | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | suppressed |
| Nystatin | Nystatin | 48 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 28 |
| Promethazine Hcl | Promethazine Hcl | 48 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 48 | suppressed |
| Finasteride | Finasteride | 46 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 16 |
| Acyclovir | Acyclovir | 41 | suppressed |
| Calcitriol | Calcitriol | 41 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 40 | suppressed |
| Entacapone | Entacapone | 40 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Lamivudine | Lamivudine | 38 | suppressed |
| Tivicay | Dolutegravir Sodium | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Novolog | Insulin Aspart | 36 | suppressed |
| Ozempic | Semaglutide | 36 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 15 |
| Pilocarpine Hcl | Pilocarpine Hcl | 31 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 27 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Digoxin | Digoxin | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Trulicity | Dulaglutide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Admelog | Insulin Lispro | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,488.77 · 84 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, EVENITY, FANAPT, FARXIGA, GIVLAARI, INSPIRE, KISUNLA, KRYSTEXXA, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SYNTHROID, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error